🇺🇸 US Stock Screener ← Switch market ★ Elite Club ⚡ HerAI

PALI PALI

Company Profile ↓
$2.12
+103.85% 1Y
Mkt Cap$338.45M
P/E-7.07
P/B2.62
52W High$2.80
52W Low$0.54
Book Value$0.81
EPS (TTM)$-0.30

Company Overview

PALI (PALI) is a publicly traded company listed on with a market capitalization of $338.45M. The valuation, growth and price-trend signals below summarize what matters most to investors and traders evaluating the stock.

Why Investors Should Care

Conservative Balance Sheet

Carries low leverage with a debt-to-equity ratio of 0.05.

Growth & Price Performance

Stock Price Performance

1 Year:+103.85%
6 Months:+27.71%
3 Months:+7.61%
1 Month:+1.92%

Highlights auto-generated from reported financials and price data; not investment advice. Verify with official filings before acting.

Technical Snapshot Bullish
52-Week Range 70% of range
$0.54 $2.80
Trend Signals
  • Price vs 50-DMAAbove
  • Price vs 200-DMAAbove
  • Golden Cross8d ago
  • RSI (14)58.53 · Neutral
Price Performance
1M+1.92%
3M+7.61%
6M+27.71%
1Y+103.85%

Auto-generated from price history and fundamentals; not investment advice.

⚙Ad space

Price Chart

Robinhood TradingView

Fundamental Growth Charts

Interactive charts for Revenue, Net Income, EBITDA, Free Cash Flow, EPS, ROE, ROCE, Gross/Net/Operating Margin and more — switch metric and period using the dropdowns above. CAGR is computed across the displayed window (quarterly CAGR is annualised). Visual growth charts make it easy to spot multi-year compounding trends at a glance — far faster than reading raw numbers in a table.

PROS

  • In a confirmed uptrend (50-DMA above 200-DMA).

CONS

No notable concerns flagged.

* The pros and cons are auto-generated from financial metrics.

⚙Ad space

Valuation

Stock P/E
-7.07
Industry PE
-
Forward P/E
-
PEG Ratio
-
Book Value
$0.81
Price to Book
2.62
P/S
-
EV/EBITDA
-
Dividend Yield
0.00%

Growth (CAGR)

Revenue 5Y
-
Profit 5Y
-
Revenue (YoY)
-
Earnings (YoY)
-

Profitability & Returns

ROCE
-13.92%
ROE
-12.97%
ROA
-12.49%
Profit Margin
-
Op Margin
-
Gross Margin
-
EPS (Latest Qtr)
$-0.05
EPS (TTM)
$-0.30

Balance Sheet & Liquidity

Debt/Equity
0.05
Quick Ratio
-
Current Ratio
28.95
Debt
$71.00K
Total Assets
$133.31M
Current Assets
$133.24M
Working Capital
$129.59M

Ownership

Promoter Holding
1.64%
Chg in Prom Hold
0.00%
FII / Inst Holding
94.37%
Chg in FII Hold
0.00%

Financial Snapshot

Enterprise Value
-
Total Revenue (TTM)
$0
EBITDA
$-16.77M
Free Cash Flow
$-10.85M
Operating Cash Flow
$-10.85M
Shares Outstanding
159.64M
Gross Margin
-
Payout Ratio
-
Financial Statements Quarterly Results · Profit & Loss · Balance Sheet · Cash Flows · Ratios

Quarterly Results

Figures in USD.

Metric Sep 2014Dec 2014Mar 2015Jun 2015Sep 2015Dec 2015Mar 2016Jun 2016Sep 2016Mar 2017Jun 2017Sep 2017Mar 2018Jun 2018Sep 2018Mar 2019Jun 2019Sep 2019Mar 2020Jun 2020Sep 2020Mar 2021Jun 2021Sep 2021Mar 2022Jun 2022Sep 2022Mar 2023Jun 2023Sep 2023Dec 2023Mar 2024Jun 2024Sep 2024Dec 2024Mar 2025Jun 2025Sep 2025Dec 2025Mar 2026
Revenue ------------------------000250.00K00-000-00000
Cost of Revenue ----------------------------------------
Gross Profit ----------------------------------------
Operating Expenses -----------------------------------2.31M2.84M2.92M9.98M10.75M
Operating Income -4.11M-4.64M-4.61M-4.99M-5.20M-4.35M-6.23M-3.83M-4.92M-4.23M-4.22M-2.59M-2.35M-2.02M-2.08M-2.46M-1.92M-2.12M-1.99M-1.84M-1.82M-1.95M-32.86M-3.02M-3.89M-3.57M-4.41M-2.53M-3.61M-3.78M--3.67M-4.21M-3.59M--2.31M-2.84M-2.92M-9.98M-10.75M
EBITDA ------------------------------------2.23M-2.78M-2.86M-8.90M-9.60M
Interest Expense -----------------------------------1.00K2.00K5.00K2.00K1.00K
Pretax Income ------------------------------------2.23M-2.78M-2.87M-8.90M-9.60M
Tax Provision ----------------------------------------
Net Income -4.46M-5.50M-5.05M-5.45M-5.64M-4.77M-6.61M-3.85M-5.22M-7.57M-4.65M-133.78K-2.15M-627.05K-1.83M-3.11M-1.44M-1.76M-2.38M-1.85M-1.84M-4.03M-31.75M8.09M-4.21M-2.34M-3.99M-2.34M-3.39M-3.60M--3.53M-4.08M-3.49M--2.23M-2.78M-2.87M-8.90M-9.60M
Diluted EPS ---------0.59---0.18---0.12-----0.67-0.66--4.100.42-12.96-5.77-4.10-8.13-7.93-7.38--4.59-3.32-2.32--0.47-0.58-0.38--0.05
R&D Expense 2.11M-3.18M3.31M3.39M-3.07M2.47M3.59M2.90M2.59M1.38M1.17M1.01M897.10K1.51M954.45K825.49K696.89K446.03K466.01K471.11K--------362.00K--16.00M-----6.00M

Profit & Loss (Annual)

Figures in USD.

Metric Dec 2009Dec 2010Dec 2011Dec 2012Dec 2013Dec 2014Dec 2015Dec 2016Dec 2017Dec 2018Dec 2019Dec 2020Dec 2021Dec 2022Dec 2023Dec 2024Dec 2025
Revenue -733.44K390.62K407.71K110.00K18.83K10.42K16.25K260.00K260.00K15.39K13.52K-0250.00K00
Cost of Revenue -----------------
Gross Profit -----------------
Operating Expenses -------------15.31M13.10M14.86M18.06M
Operating Income -10.47M-15.18M-12.99M-10.16M-12.52M-17.44M-19.16M-20.64M-13.31M-8.26M-8.63M-9.30M--15.31M-12.85M-14.86M-18.06M
EBITDA --------------14.24M-12.28M-14.42M-16.77M
Interest Expense -------------13.00K15.00K12.00K10.00K
Pretax Income --------------14.26M-12.30M-14.44M-16.78M
Tax Provision -----------------
Net Income -10.36M-18.39M-12.52M-10.12M-19.83M-22.63M-20.90M-21.07M-15.67M-4.92M-8.35M-10.32M--14.26M-12.30M-14.44M-16.78M
Diluted EPS ------------3.72--247.95-27.01-10.19-0.30
R&D Expense 5.35M9.16M7.35M6.11M7.29M8.36M12.64M13.16M8.10M3.96M4.06M2.02M---16.00M-

Balance Sheet (Annual)

Figures in USD.

Metric Dec 2008Dec 2009Dec 2010Dec 2011Dec 2012Dec 2013Dec 2014Dec 2015Dec 2016Dec 2017Dec 2018Dec 2019Dec 2020Dec 2021Dec 2022Dec 2023Dec 2024Dec 2025
Total Assets --10.59M4.09M8.75M19.41M29.84M14.95M22.60M13.88M7.68M6.58M3.02M-15.76M14.05M10.88M134.34M
Current Assets --------------14.73M13.33M10.49M134.22M
Cash & Equivalents 4.90M2.31M9.26M2.35M7.44M16.85M12.52M4.72M15.19M6.67M5.79M5.11M713.00K-12.38M12.43M9.82M133.38M
Inventory ------------------
Receivables -------------0----
Total Liabilities --2.74M2.43M1.78M11.00M12.12M9.98M11.27M5.37M1.63M1.46M10.12M-3.28M2.74M3.39M4.96M
Current Liabilities --2.74M2.43M1.76M5.94M4.01M6.43M7.33M1.51M1.05M1.22M8.08M-3.01M2.59M3.24M4.64M
Long Term Debt ----04.93M8.06M3.38M----94.00K-----
Total Debt --------------404.00K369.00K169.00K71.00K
Total Equity -2.56M-5.02M7.85M1.66M6.97M8.42M17.72M4.97M11.33M8.52M6.05M-8.33M-16.60M-12.48M11.31M7.49M129.38M
Shares Outstanding --------------396.29K818.06K2.97M159.64M

Cash Flows (Annual)

Figures in USD.

Metric Dec 2009Dec 2010Dec 2011Dec 2012Dec 2013Dec 2014Dec 2015Dec 2016Dec 2017Dec 2018Dec 2019Dec 2020Dec 2021Dec 2022Dec 2023Dec 2024Dec 2025
Operating Cash Flow -5.14M-9.98M-8.10M-8.48M----15.62M-13.42M-7.69M-7.26M-4.77M--13.36M-11.13M-12.19M-10.85M
Investing Cash Flow -210.78K-332.68K-480.85K-254.86K---2.36M-94.05K5.00M--6.00K-54.00K-10.00K-4.00K0-
Financing Cash Flow 2.76M17.27M1.67M13.82M---23.74M4.99M1.81M6.59M1.89M-15.26M11.19M9.58M134.44M
Capital Expenditure -88.38K-76.32K-196.41K-39.22K-125.36K-207.89K-176.27K-98.09K-11.40K-1.71K--6.00K--10.00K-4.00K--
Free Cash Flow -5.23M-10.06M-8.29M-8.52M----15.71M-13.43M-7.69M--4.77M--13.37M-11.14M-12.19M-10.85M
Net Change in Cash -------------1.89M49.00K-2.61M123.59M

Ratios (Annual)

Figures in %.

Metric Dec 2009Dec 2010Dec 2011Dec 2012Dec 2013Dec 2014Dec 2015Dec 2016Dec 2017Dec 2018Dec 2019Dec 2020Dec 2021Dec 2022Dec 2023Dec 2024Dec 2025
Gross Margin % -----------------
Operating Margin % --2,070.4%-3,325.6%-2,491.1%-11,385.4%-92,581.4%-183,896.8%-127,027.2%-5,118.1%-3,176.7%-56,071.8%-68,764.8%---5,138.0%--
Net Margin % --2,507.0%-3,204.7%-2,482.5%-18,029.0%-120,154.7%-200,671.0%-129,721.8%-6,025.4%-1,894.1%-54,252.6%-76,346.2%---4,920.0%--
ROE % 206.6%-234.1%-754.2%-145.2%-235.6%-127.7%-420.8%-186.0%-184.0%-81.4%100.2%62.2%--114.3%-108.7%-192.7%-13.0%
ROCE % --193.3%-782.6%-145.2%-92.9%-67.5%-224.7%-135.1%-107.6%-124.5%-161.1%183.6%--120.1%-112.0%-194.4%-13.9%

Shareholding Pattern

Insiders
1.64%
Institutions
94.37%
Public Float
95.94%

Analyst View

Loading analyst coverage…

Latest News

Recent headlines for PALI

Yahoo Finance Mon, 27 Jul 2026

Palisade Bio Draws Bullish Call, Lead IBD Drug Advances Toward Phase 2

Oppenheimer on Thursday initiated coverage of Palisade Bio Inc., saying the stock offers investors an attractive way to gain exposure to the fast-growing inflammatory bowel disease market. The company’s lead candidate, PALI-2108, is a once-…

Yahoo Finance Fri, 10 Jul 2026

Palisade Bio to Participate in the Leerink Partners Therapeutics Forum

Management to participate in investor meetings on July 14-15 in Boston Denver, CO, July 10, 2026 (GLOBE NEWSWIRE) -- Palisade Bio, Inc. (Nasdaq: PALI) (“Palisade” or the “Company”), a clinical-stage biopharmaceutical company developing next…

Yahoo Finance Mon, 29 Jun 2026

PALI Stock Heads For Best Day In Seven Months – What’s Driving Today’s Rally?

Palisade Bio received clearance from the U.S. Food and Drug Administration for its Investigational New Drug application for PALI-2108, an ulcerative colitis treatment.

Yahoo Finance Mon, 29 Jun 2026

Palisade Bio Receives FDA Clearance of IND for PALI-2108 and Plans to Initiate Global Phase 2 ASCENTRA-UC Study in Ulcerative Colitis

ASCENTRA-UC expected to enroll up to 204 patients with moderately to severely active ulcerative colitis across North America and Europe First patient enrollment anticipated in the second half of 2026; primary efficacy results expected in th…

Yahoo Finance hu, 11 Jun 2026

Palisade Bio Welcomes Biopharmaceutical Industry Veterans Robert Baltera and Jordan Zwick to its Board of Directors

Board strengthened with extensive biotechnology leadership, strategic transactions and capital markets expertise Company continues to build on PALI-2108 clinical progress as it advances toward Phase 2 development and additional key mileston…

Yahoo Finance ue, 09 Jun 2026

Palisade Bio to Present on the Potential of PALI-2108 for Fibrostenotic Crohn’s Disease at New York Academy of Sciences Symposium

Presentation to highlight fibrostenotic Crohn’s disease biology and the potential of a locally bioactivated PDE4 inhibitor prodrug approach Denver, CO, June 09, 2026 (GLOBE NEWSWIRE) -- Palisade Bio, Inc. (Nasdaq: PALI) (“Palisade” or the “…

PALI — Frequently Asked Questions

What is the current share price of PALI?

As of 2026-08-05 17:25 PDT, PALI trades at $2.12 on NASDAQ/NYSE. Its 52-week range is $0.54 to $2.80.

What is the market capitalisation of PALI?

PALI has a market capitalisation of $338.45M on NASDAQ/NYSE.

What is the P/E ratio of PALI?

PALI trades at a trailing price-to-earnings (P/E) ratio of -7.07. Its price-to-book (P/B) ratio is 2.62.

What is the return on equity (ROE) of PALI?

PALI has a return on equity (ROE) of -12.97%. Its return on capital employed (ROCE) is -13.92%.

Is PALI a good stock to buy?

This page provides a data-driven analysis of PALI, including valuation ratios, profitability, growth trends, auto-generated pros and cons, peer comparison and AI exposure. Review these fundamentals alongside your own research and risk tolerance. This is informational content, not investment advice.

Explore More

🔍 All Stock Screens 📈 Technical Screens 💰 Fundamental Screens 🔄 Swing Trading Setups 📐 Chart Patterns 📅 Earnings Calendar 📋 All USA Stocks
⚙Ad space